Provision of healthcare is a key topic globally with increasing populations worldwide, increasing healthcare system costs, multiple humanitarian crises, and supply chain concerns. Two weeks ago in Dublin, Medicines for Europe brought together industry leaders and experts to discuss better access to medicines in hopes of addressing at least some these issues.
Generic medicines play a key role in our healthcare systems worldwide, in the provision of patient care and healthcare cost savings. The availability of cost-effective generic medicines has driven increased access to life-saving treatments for millions of patients in Europe. Off-patent medicines constitute 70% of all medications sold in Europe by volume, which leads to significant cost savings for healthcare systems; however, the added societal benefits of generic medicines are not often recognized.
The white paper Beneath the Surface: Unravelling the True Value of Generic Medicines (April 2024) by IQVIA highlights the societal value of generics into the four key areas below. These concepts were critical in setting the stage for dynamic discussions over the conference’s two days in relation to the value proposition of generics and biosimilars, evolution of the off-patent sector, supply chain security for critical medicines, and crisis management, as well as the future and sustainability of European pharma manufacturing.
Lachman Consultants is proud to support Medicines for Europe’s objective of increasing the health and wellbeing of all Europeans through better access to high-quality medicines.
Source: Beneath the Surface: Unravelling the True Value of Generic Medicines, White paper by IQVIA, April 2024
